- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Boehringer Ingelheim's Jascayd approved by MHRA for idiopathic pulmonary fibrosis | ||
| Fr | Ipsen to acquire Memo Therapeutics in deal worth more than €700m | ||
| Do | Medical-Commercial alignment in rare disease launches: what breaks first? | ||
| Do | Teva submits FDA application for paediatric Tourette syndrome therapy | ||
| Mi | Vertex to acquire Crinetics in deal worth around $10.0bn | ||
| Mi | The UK's life sciences' crossroads: competing in a market defined by speed, scale and investment | ||
| Di | Novartis to acquire Myricx Bio in deal worth $1.5bn | ||
| Di | Launching into an AI-powered future: a prescription for success | ||
| Mo | Klick Health acquires Oxford PharmaGenesis | ||
| Mo | ASCO 2026: the art of translation | ||
| 03.07. | Communiqué Awards 2026: Healthcare Communiquétor Neil Flash | ||
| 03.07. | Communiqué Awards 2026: celebrating excellence in healthcare communications | ||
| 02.07. | Sanofi announces phase 3 study data for infantile-onset Pompe disease | ||
| 02.07. | The outcomes economy: where next for pharma? | ||
| 01.07. | Zymeworks to acquire Theravance Biopharma in deal worth $929m | ||
| 01.07. | Achieving launch excellence through cross-functional collaboration | ||
| 30.06. | Roche's Enspryng given FDA Priority Review as thyroid eye disease treatment | ||
| 30.06. | Steering generative AI into the pharma fast lane | ||
| 29.06. | Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim | ||
| 26.06. | Pfizer announces phase 3 results for potential non-small cell lung cancer treatment | ||
| 26.06. | MRM Health appoints Hans-Jürgen Wörle as Independent Director | ||
| 25.06. | MRM Health appoints Michel Detheux as Chairman of the Board | ||
| 25.06. | Gilead's Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer | ||
| 24.06. | Sanofi's Cenrifki approved in Europe for secondary progressive MS without relapses | ||
| 24.06. | Lundbeck appoints Tarek Samad as EVP, Head of Research & Development |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.